KRAS and colorectal carcinoma: Our result demonstrated that the combination treatment with 4-AAQB and cetuximab could synergistically overcome the resistance of KRAS-mutant CRC cells (SW1463) and KRAS-wild (Caco-2) cells to cetuximab.